|
1
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schlansky B and Sonnenberg A: Epidemiology
of noncardia gastric adenocarcinoma in the United States. Am J
Gastroenterol. 106:1978–1985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y and
Wang X: ERCC1 siRNA ameliorates drug resistance to cisplatin in
gastric carcinoma cell lines. Mol Med Rep. 9:2423–2428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Silva IU, McHugh PJ, Clingen PH and
Hartley JA: Defects in interstrand cross-link uncoupling do not
account for the extreme sensitivity of ERCC1 and XPF cells to
cisplatin. Nucleic Acids Res. 30:3848–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buhagiar A and Ayers D: Chemoresistance,
cancer stem cells, and miRNA influences: The case for
neuroblastoma. Anal Cell Pathol. 2015:1506342015. View Article : Google Scholar
|
|
7
|
Han LP, Fu T, Lin Y, Miao JL and Jiang QF:
MicroRNA-138 negatively regulates non-small cell lung cancer cells
through the interaction with cyclin D3. Tumour Biol. 37:291–298.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin Z, Guan L, Song Y, Xiang GM, Chen SX
and Gao B: MicroRNA-138 regulates chemoresistance in human
non-small cell lung cancer via epithelial mesenchymal transition.
Eur Rev Med Pharmacol. 20:1080–1086. 2016.
|
|
9
|
Wang Q, Zhong M, Liu W, Li J, Huang J and
Zheng L: Alterations of microRNAs in cisplatin-resistant human
non-small cell lung cancer cells (A549/DDP). Exp Lung Res.
37:427–434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Golubovskaya VM, Sumbler B, Ho B, Yemma M
and Cance WG: miR-138 and miR-135 directly target focal adhesion
kinase, inhibit cell invasion, and increase sensitivity to
chemotherapy in cancer cells. Anticancer Agents Med Chem. 14:18–28.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: miR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma Cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: miR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie XQ, Zhao QH, Wang H and Gu KS:
Dysregulation of mRNA profile in cisplatin-resistant gastric cancer
cell line SGC7901. World J Gastroenterol. 23:1189–1202. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sileni VC, Fosser V, Maggian P, Padula E,
Beltrame M, Nicolini M and Arslan P: Pharmacokinetics and tumor
concentration of intraarterial and intravenous cisplatin in
patients with head and neck squamous cancer. Cancer Chemother
Pharmacol. 30:221–225. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang H, Luo J, Liu Z, Zhou R and Luo H:
MicroRNA-138 regulates DNA damage response in small cell lung
cancer cells by directly targeting H2AX. Cancer Invest. 33:126–236.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Yang K, Sun X, Fang P, Shi H, Xu J,
Xie M and Li M: miR-138 suppresses airway smooth muscle cell
proliferation through the PI3K/AKT signaling pathway by targeting
PDK1. Exp Lung Res. 41:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma F, Zhang M, Gong W, Weng M and Quan Z:
miR-138 suppresses cell proliferation by targeting Bag-1 in
gallbladder carcinoma. PLoS One. 10:e01264992015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X,
Deng Y, Jiang J and Sun C: MicroRNA-138-5p regulates pancreatic
cancer cell growth through targeting FOXC1. Cell Oncol (Dordr).
38:173–181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen P, Zeng M, Zhao Y and Fang X:
Upregulation of Limk1 caused by microRNA-138 loss aggravates the
metastasis of ovarian cancer by activation of Limk1/cofilin
signaling. Oncol Rep. 32:2070–2076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan XH, Nama S, Gopal F, Rizk P, Ramasamy
S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al:
Targeting glioma stem cells by functional inhibition of a
prosurvival oncomiR-138 in malignant gliomas. Cell Rep. 2:591–602.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stojcheva N, Schechtmann G, Sass S, Roth
P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis
FJ, et al: MicroRNA-138 promotes acquired alkylator resistance in
glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Oncotarget. 7:12937–12950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Pascale F, Nama S, Muhuri M, Quah S,
Ismail HM, Chan XHD, Sundaram GM, Ramalingam R, Burke B and Sampath
P: C/EBPbeta mediates RNA polymerase III-driven transcription of
oncomiR-138 in malignant gliomas. Nucleic Acids Res. 46:336–349.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A
and Zheng Y: Prognostic potential of microRNA-138 and its target
mRNA PDK1 in sera for patients with non-small cell lung cancer. Med
Oncol. 31:1292014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Postel-Vinay S and Soria JC: ERCC1 as
predictor of platinum benefit in non-small-cell lung cancer. J Clin
Oncol. 35:384–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du P, Wang Y, Chen L, Gan Y and Wu Q: High
ERCC1 expression is associated with platinum-resistance, but not
survival in patients with epithelial ovarian cancer. Oncol Lett.
12:857–862. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muallem MZ, Marnitz S, Richter R, Kohler
C, Sehouli J and Arsenic R: ERCC1 expression as a predictive marker
of cervical cancer treated with cisplatin-based chemoradiation.
Anticancer Res. 34:401–406. 2014.PubMed/NCBI
|
|
30
|
Li S, Wu J, Chen Y, Tang W, Peng Q, Deng
Y, Xie L, Wang J, Huang S, Li R, et al: ERCC1 expression levels
predict the outcome of platinum-based chemotherapies in advanced
bladder cancer: A meta-analysis. Anticancer Drugs. 25:106–114.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan J, Chao L, Lee AC and Chen Q: Higher
expression of ERCC1 may be associated with resistance to adjuvant
platinum-based chemotherapy in gastric cancer. Cancer Invest.
35:85–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stevens EV, Nishizuka S, Antony S, Reimers
M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC and Pommier
Y: Predicting cisplatin and trabectedin drug sensitivity in ovarian
and colon cancers. Mol Cancer Ther. 7:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie QH, He XX, Chang Y, Sun SZ, Jiang X,
Li PY and Lin JS: miR-192 inhibits nucleotide excision repair by
targeting ERCC3 and ERCC4 in HepG2.2.15 cells. Biochem Biophys Res
Commun. 410:440–445. 2011. View Article : Google Scholar : PubMed/NCBI
|
